






BRITROC-1

age: 81  
 stage: 33  
 platinum status: resistant  
 prior lines: 1




drug ■ Carboplatin ■ PLD







group ● diagnosis ● relapse ● patient sample

BRITROC-106

age: 66  
 stage: 33  
 platinum status: sensitive  
 prior lines: 2




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD ■ Rucaparib







group ● diagnosis ● relapse ● patient sample

BRITROC-11

age: 74  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug Carboplatin + Paclitaxel Carboplatin + PLD







group diagnosis relapse patient sample

# BRITROC-124

age: 63  
stage: 33  
platinum status: sensitive  
prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

BRITROC-132

age: 68  
 stage: 32  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Bevacizumab + Carboplatin + Gemcitabine







group ● diagnosis ● relapse ● patient sample

BRITROC-147

age: 57  
 stage: 4  
 platinum status: resistant  
 prior lines: 1




drug ■ Carboplatin ■ Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

# BRITROC-148

age: 74  
stage: 4  
platinum status: resistant  
prior lines: 2




drug ■ Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

# BRITROC-157

age: 67  
stage: 4  
platinum status: sensitive  
prior lines: 1



drug Carboplatin Carboplatin + PLD




group diagnosis relapse patient sample







# BRITROC-187

age: 77  
stage: 11  
platinum status: sensitive  
prior lines: 1




drug ■ Carboplatin







group ● diagnosis ● relapse ● patient sample

# BRITROC-192

age: 48  
stage: 33  
platinum status: sensitive  
prior lines: 1




drug Carboplatin + Paclitaxel







BRITROC-2

age: 73  
 stage: 33  
 platinum status: resistant  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ PLD







group ● diagnosis ● relapse ● patient sample

BRITROC-204

age: 50  
 stage: 22  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin







group ● diagnosis ● relapse ● patient sample

BRITROC-205

age: 53  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

# BRITROC-209

age: 42  
stage: 33  
platinum status: sensitive  
prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

# BRITROC-216

age: 70  
stage: 32  
platinum status: sensitive  
prior lines: 1




drug ■ Bevacizumab + Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

# BRITROC-225

age: 46  
stage: 33  
platinum status: sensitive  
prior lines: 1



drug ■ Carboplatin + Paclitaxel ■ Carboplatin




group ● diagnosis ● relapse ● patient sample







BRITROC-226

age: 70  
 stage: 32  
 platinum status: sensitive  
 prior lines: 1




drug  Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

# BRITROC-229

age: 75  
stage: 33  
platinum status: resistant  
prior lines: 1




drug ■ Carboplatin ■ Avelumab







group ● diagnosis ● relapse ● patient sample

# BRITROC-23

age: 47  
stage: 33  
platinum status: sensitive  
prior lines: 2




drug Carboplatin + Paclitaxel Carboplatin + PLD







group diagnosis relapse patient sample

BRITROC-232

age: 63  
 stage: 22  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin







group ● diagnosis ● relapse ● patient sample

BRITROC-234

age: 63  
 stage: 4  
 platinum status: resistant  
 prior lines: 1




drug ■ Bevacizumab + Carboplatin + Paclitaxel ■ AZD2014/Placebo + Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-241

age: 53  
 stage: 4  
 platinum status: sensitive  
 prior lines: 3




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







# BRITROC-242

age: 78  
stage: 33  
platinum status: sensitive  
prior lines: 1




drug  Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-246

age: 61  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1



drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD




group ● diagnosis ● relapse ● patient sample







BRITROC-248

age: 56  
 stage: 4  
 platinum status: resistant  
 prior lines: 2




drug Carboplatin + Paclitaxel Carboplatin + PLD + Olaparib Paclitaxel







group diagnosis relapse patient sample

BRITROC-256

age: 63  
 stage: 33  
 platinum status: sensitive  
 prior lines: 2




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD + Rucaparib/Placebo ■ Carboplatin







group ● diagnosis ● relapse ● patient sample

BRITROC-259

age: 52  
 stage: 31  
 platinum status: sensitive  
 prior lines: 2




drug ■ Carboplatin + Paclitaxel ■ Bevacizumab + Carboplatin + Gemcitabine ■ Cisplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-260

age: 73  
 stage: 21  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-267

age: 57  
 stage: 32  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

BRITROC-268

age: 60  
 stage: 33  
 platinum status: resistant  
 prior lines: 2




drug ■ Bevacizumab + Carboplatin + Paclitaxel ■ Carboplatin + PLD ■ Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-271

age: 70  
 stage: 23  
 platinum status: sensitive  
 prior lines: 1




drug  Carboplatin + Paclitaxel







group ● diagnosis ● relapse ● patient sample

BRITROC-274

age: 53  
 stage: 22  
 platinum status: sensitive  
 prior lines: 2



drug ■ Carboplatin + Paclitaxel ■ Letrozole ■ Carboplatin + PLD










# BRITROC-32

age: 70

stage: 33

platinum status: resistant


prior lines: 1







group ● diagnosis ● relapse ● patient sample

BRITROC-34

age: 75  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

# BRITROC-36

age: 66  
stage: 32  
platinum status: sensitive  
prior lines: 1




drug  Carboplatin







BRITROC-37

age: 50  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug ■ Bevacizumab + Carboplatin + Paclitaxel ■ Carboplatin







group ● diagnosis ● relapse ● patient sample

BRITROC-39

age: 64  
 stage: 31  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Carboplatin + PLD







group ● diagnosis ● relapse ● patient sample

BRITROC-5

age: 49  
 stage: 33  
 platinum status: sensitive  
 prior lines: 2



drug ■ Carboplatin + Paclitaxel ■ Cisplatin + PLD



group ● diagnosis ● relapse ● patient sample





# BRITROC-55

age: 58

stage: 13

platinum status: sensitive


prior lines: 2







group ● diagnosis ● relapse ● patient sample

BRITROC-65

age: 70  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1



drug ■ Carboplatin + Paclitaxel ■ Bevacizumab + Carboplatin + Gemcitabine




group ● diagnosis ● relapse ● patient sample







BRITROC-67

age: 68  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug ■ Carboplatin + Paclitaxel ■ Bevacizumab + Carboplatin + Gemcitabine







group ● diagnosis ● relapse ● patient sample

BRITROC-74

age: 64  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug Carboplatin + Paclitaxel







group diagnosis relapse patient sample

BRITROC-8

age: 60  
 stage: 22  
 platinum status: sensitive  
 prior lines: 1




drug Carboplatin







group diagnosis relapse patient sample

BRITROC-9

age: 47  
 stage: 33  
 platinum status: sensitive  
 prior lines: 1




drug   Carboplatin + Paclitaxel   Carboplatin







group ● diagnosis ● relapse ● patient sample

BRITROC-94

age: 71  
 stage: 22  
 platinum status: sensitive  
 prior lines: 2



drug Carboplatin + Paclitaxel Cisplatin + Paclitaxel Rucaparib



group diagnosis relapse patient sample





# BRITROC-96

age: 64

stage: 32

platinum status: resistant


prior lines: 4







group ● diagnosis ● relapse ● patient sample

BRITROC-99

age: 63  
 stage: 4  
 platinum status: sensitive  
 prior lines: 1



drug ■ Carboplatin + Paclitaxel ■ Carboplatin + Gemcitabine



group ● diagnosis ● relapse ● patient sample